Statement by Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, Applauding FDA for Making GDUFA a Public Health Priority, Improving ANDA Submission Inquiry Communication

Published Online: Friday, January 31, 2014
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (January 31, 2014) — “The generic pharmaceutical industry and the Food and Drug Administration (FDA) share the view that the Generic Drug User Fee Act (GDUFA) and its obligations are a public health priority. The Generic Pharmaceutical Association (GPhA) applauds the FDA for committing to making the Abbreviated New Drug Application (ANDA) process more timely and predictable.

The intent of GDUFA is to speed consumer access to safe, lower cost generic medicines. The Generic Pharmaceutical Association (GPhA) commends the Office of Generic Drugs (OGD) for taking the appropriate steps to meet GDUFA goals, which will be measured in years 3-5.

With these communication enhancements to the ANDA review process, FDA continues to demonstrate its commitment to continuous improvement of the approval process. These changes are positive steps that can make it significantly easier for industry to assess the status of submissions, and improve market launch planning.

GPhA will continue working with the FDA’s OGD to improve process transparency and help patients, consumers, government, businesses and others gain timely access to more affordable medicine.”
Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
Mylan Inc. today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$